Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
ADC Performance Mediated by Cathepsin B in DS8201a and GGFG-DxD Systems ...
FDA批准首个非小细胞肺癌HER2突变的靶向药物Enhertu(DS-8201a,T-DXd)上市,这些知识点你都知道吗-无癌家园
DS-8201a - 平头哥
首款！不限癌种，重磅ADC获FDA加速批准
Summary of Approved HER2 ADCs on The Market & in Clinical Trials ...
FDA授予Enhertu(DS8201、trastuzumab deruxtecan、T-DXd)治疗HER2低表达的乳腺癌突破性疗法指定-无癌家园
The Latest Research and Development into the Antibody–Drug Conjugate ...
深度挖掘DS-8201a！期待下一个破局者 - 知乎
万字长文！深度挖掘DS-8201a！期待下一个破局者|肿瘤_新浪财经_新浪网
DS-8201a Sensitive Cell Line_药靶模型_南京科佰生物科技有限公司
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug ...
新型靶向药物DS-8201a和T-DM1疗效喜人！肺癌患者福音！
Enhertu ® (fam-trastuzumab deruxtecan-nxki or DS-8201a) formula, ADC ...
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I ...
DS-8201a Resistant Cell Line_药靶模型_南京科佰生物科技有限公司
Trastuzumab deruxtecan (DS-8201a) for Breast Cancer Clinical Trial 2023 ...
A HER2-Targeting Antibody–Drug Conjugate, Trastuzumab Deruxtecan (DS ...
Ds-8201A – Application in Therapy and Current Clinical Research
晚期胃癌新药DS-8201(DS8201、Trastuzumab Deruxtecan、T-DXd)、ZW25、AMG199未来可期_全球肿瘤医生网
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2 ...
Safety, pharmacokinetics, and antitumour activity of trastuzumab ...
DS-8201a | Semantic Scholar
SABCS2019速递丨从独特药物作用机制看新型药物DS-8201a优势，为抗HER2治疗开启新篇_研究
Combination effect of DS-8201a and anti-CTLA-4 antibody. Antitumor ...
FDA批准首个非小细胞肺癌HER2突变的靶向药物Enhertu(DS-8201a,T-DXd)上市,这些知识点你都知道吗_全球肿瘤医生网
DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a ...
Bystander killing effect of DS‐8201a, a novel anti‐human epidermal ...
Case Study - Quantification of DS-8201a and its pharmacokinetics in ...
放射性核素标记技术在抗体偶联药物（ADC）药代动力学研究中的应用 - 药明康德DMPK
ADC之蛋白酶可裂解连接子 - 知乎
Antitumor effect of DS-8201a in EMT6-hHER2 syngeneic mouse model. A ...
DS-8201_胃癌_抗癌药物_全球肿瘤医生网
(PDF) Bystander killing effect of DS-8201a, a novel anti-HER2 antibody ...
(PDF) [Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor ...
Co-Clinical Study of [fam-] Trastuzumab Deruxtecan (DS8201a) in Patient ...
Trastuzumab deruxtecan (DS-8201a), a HER2-Targeting Antibody-Drug ...
奥简科技推出125V/80mA，3uA高压低静态功耗、高性能LDO DS8201
Trastuzumab-deruxtecan (DS-8201a, T-DXd) | Antibody-Drug Conjugate ...
14个临床研究为你全面解读最新上市的DS-8201用药信息|乳腺癌|DXd|抑制剂|ADC|用药|药物|肿瘤|-健康界
第一三共2022：DS-8201销售额12.6亿美元 Armstrong 2023年2月2日，第一三共公布最新季报，日本企业的财年为当年4月1 ...
SMT evaluation of trastuzumab-deruxtecan (DS-8201a). Left: Tumor volume ...
[Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is ...
ADC定点偶联技术 - 知乎
FDA批准首个乳腺癌HER2低表达的靶向药物Enhertu(DS-8201a、T-DXd、Fam-trastuzumab Deruxtecan ...
阿斯利康DS8201临床试验,评估DS8201(Trastuzumab Deruxtecan、T-DXd)一线治疗携带HER2突变的不可切除 ...
ENHERTU(DS-8201a)说明书 - 知乎
已上市ADC：专利布局全景分析
我想了解一下DS8201_的作用机制的答案_行行查_行业研究数据库
普众发现团队揭示DS-8201a/Trodelvy ADC耐药机制，展示“后8201”ADC技术平台医药新闻-ByDrug-一站式医药资源共享 ...
盘点工业生产抗体-药物偶联物(ADC)的几种偶联技术 - 知乎
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
Bystander killing effect of DS-8201a, a novel anti-human epidermal ...
%20for%20Breast%20Cancer.png?md=1)
30097-X.jpg)
30604-6/asset/fa133f3d-73da-45fe-8ea3-4842ec649559/main.assets/gr1_lrg.jpg)
